Related Experiment Video
Updated: Jul 5, 2026
Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
Published on: December 16, 2022
Construction of human-SCID chimeric mice
Maria Grazia Roncarolo1, José M Carballido2
1University of Turin, Turin, Italy.
Abstract:
Until recently, testing of new therapeutic agents has relied extensively upon the use of mice and nonhuman primates for in vivo preclinical studies. Unfortunately, these animal models do not always mimic the physiological and pathophysiological processes that occur in humans. The finding that C.B-17 severe combined immunodeficiency (SCID) mice lack a competent immune system, and therefore are unable to mount effective cellular and humoral responses to foreign antigens, has led to their use as recipients for xenografts of human tissues. This unit is focused on the construction of human-SCID chimeric through the surgical implantation of human fetal hematolymphoid tissues into SCID mice (SCID-hu mice). The Basic Protocol describes the surgical implantation of human fetal thymus and liver under the kidney capsules of SCID mice (SCID-hu Thy/Liv model). Subcutaneous transplantation of human fetal bone marrow and thymus (SCID-hu Bm/Thy mice) is described in the Alternate Protocol. Additional support protocols provide procedures to analyze human lymphocyte populations in the peripheral blood and grafted organs of SCID-hu mice. The advantages and disadvantages of each protocol and potential applications are discussed in the Commentary.
Insights
Severe combined immunodeficiency (SCID) mice are used for human tissue xenografts, creating SCID-human (SCID-hu) mice. These models improve preclinical studies by better mimicking human physiology than traditional animal models.
Area of Science:
- Immunology
- Transplantation Biology
- Preclinical Research
Background:
- Traditional animal models like mice and nonhuman primates often fail to accurately replicate human physiological and pathophysiological processes.
- The limitations of existing models necessitate the development of more human-relevant preclinical systems.
- Severe combined immunodeficiency (SCID) mice offer a unique model due to their lack of a competent immune system, preventing rejection of foreign tissues.
Purpose of the Study:
- To detail the construction of SCID-human (SCID-hu) chimeric mice by xenografting human fetal hematolymphoid tissues.
- To provide protocols for establishing SCID-hu mouse models for enhanced preclinical therapeutic agent testing.
- To discuss the advantages, disadvantages, and applications of different SCID-hu mouse models.
Main Methods:
- Surgical implantation of human fetal thymus and liver under the kidney capsules of SCID mice (SCID-hu Thy/Liv model).
- Subcutaneous transplantation of human fetal bone marrow and thymus into SCID mice (SCID-hu Bm/Thy model).
- Protocols for analyzing human lymphocyte populations in peripheral blood and grafted organs of SCID-hu mice.
Main Results:
- Successful construction of SCID-hu chimeric mice engrafted with human fetal tissues.
- Demonstration of methods to analyze human immune cell populations within the SCID-hu model.
- Establishment of distinct SCID-hu models (Thy/Liv and Bm/Thy) for varied research applications.
Conclusions:
- SCID-hu mice provide a more accurate preclinical model for studying human immune system development and function.
- These xenograft models facilitate the testing of therapeutic agents in a humanized system.
- The described protocols offer valuable tools for immunological research and drug development.
